Recent news of the possible complications of blood clots – or Thrombosis with Thrombocytopenia Syndrome (TTS) – following the AstraZeneca/Oxford and Johnson & Johnson/Janssen COVID-19 vaccines have raised public concerns and questions about vaccine safety. Once TTS emerged as a safety concern, the Brighton Collaboration was invited by the European Medicines Agency (EMA) to rapidly develop an interim case definition for case finding purposes. As next steps, Brighton is organizing a process to collect and share more complete information on the possible cases that meet the case finding definition. This will hopefully aid the investigations into whether or not the illness could be linked to the vaccination, and the development of a final case definition for TTS.
Much has been learned about the need for vaccine safety surveillance through COVAX and other recent collaborative efforts. Here, w...
